Evidence map›Paper›PMID 39632077›Full record

ArticleAlcohol, clinical & experimental research2025

Demographic and clinical characteristics associated with utilization of alcohol use disorder treatment in a multicenter study of patients with alcohol-associated cirrhosis.

Jeremy W Luk, Nghiem B Ha, Amy M Shui, Hannah R Snyder, Steven L Batki, Michael J Ostacher, Alexander Monto, Robert J Wong, Ramsey Cheung, Priti Parekh and 7 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alcohol, clinical & experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05191446 (Impact of the Coronavirus 2019), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05191446 naactive not recruitingnot on this map

Impact of the Coronavirus 2019 (COVID-19) Pandemic on Patient Outcomes, Telehealth Care Delivery, and Treatment for Unhealthy Alcohol Use in Vulnerable Patients With Advanced Liver Disease Across Two Healthcare Systems

TypeinterventionalSponsorUniversity of California, San FranciscoRan2022 to 2026Enrolled180ConditionsLiver Diseases, Alcohol Use DisorderArmsStepped alcohol intervention (SAT) to reduce unhealthy alcohol use, Usual Care (UC)
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Bereavement, prolonged grief, and the prevention of alcohol misuse.Alcohol, clinical & experimental research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jeremy W LukOffice of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-9061-1555
Nghiem B HaDivision of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, California, USA.
Amy M ShuiDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Hannah R SnyderDepartment of Family and Community Medicine, University of California, San Francisco, California, USA.
Steven L BatkiDepartment of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
Michael J OstacherDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA.
Alexander MontoDivision of Gastroenterology and Hepatology, Veterans Affairs San Francisco Health Care System, San Francisco, California, USA.
Robert J WongDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
Ramsey CheungDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
Priti ParekhDepartment of Psychology, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
William HuaDepartment of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
D Andrew TompkinsDepartment of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
Taylor FakadejDivision of Gastroenterology and Hepatology, Zuckerberg San Francisco General Hospital, San Francisco, California, USA.
Christina G HaightDivision of Gastroenterology and Hepatology, Veterans Affairs San Francisco Health Care System, San Francisco, California, USA.
Meimei LiaoGastroenterology Section, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
Mandana KhaliliDivision of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-9178-9139
Derek D SatreDepartment of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
NRSA Hepatology Training GrantT32DK060414 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mandana Khalili, JACQUELYN J. MAHER · 2002 to 2026
$6.8M
Impact of the COVID-19 pandemic on patient outcomes, telehealth care delivery, and treatment for unhealthy alcohol use in vulnerable patients with advanced liver disease across two healthcare systemsR01AA029312 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KHALILI, MANDANA, SATRE, DEREK D · 2021 to 2025
$3.5M
Mentoring Multidisciplinary Patient-Oriented Research in Viral HepatitisK24AA022523 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KHALILI, MANDANA · 2013 to 2023
$1.9M
Mentoring alcohol use intervention research in HIV health care settingsK24AA025703 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Derek D Satre · 2018 to 2026
$1.8M
American Association for the Study of Liver Diseases AHL23-134591NIAAA NIH HHS K24 AA022523NIAAA NIH HHS K24AA022523NIAAA NIH HHS K24 AA025703NIAAA NIH HHS K24AA025703NIAAA NIH HHS R01 AA029312NIAAA NIH HHS R01AA029312NIDDK NIH HHS P30 DK026743NIDDK NIH HHS P30DK026743NIDDK NIH HHS T32 DK060414NIDDK NIH HHS T32DK060414
6 · The paper itself

Abstract

backgroundAlcohol use disorder (AUD) treatment can help improve clinical outcomes among patients with alcohol-associated cirrhosis but is underutilized. Among socioeconomically disadvantaged patients with alcohol-associated cirrhosis, we examined rates of lifetime and past 12-month AUD treatment utilization and associated demographic and clinical characteristics.

methodsRacial/ethnically diverse patients with alcohol-associated cirrhosis who had at least one hepatology clinic visit in the prior 6 months were recruited from three Northern California medical centers serving veterans and safety-net populations. Participants self-reported their AUD treatment utilization, liver disease quality of life (LDQoL), history and current symptoms of anxiety and depression, and problematic drinking as measured by the Alcohol Use Disorders Identification Test (AUDIT). Clinical measures including liver disease severity were captured from medical records.

resultsAmong 196 participants, the majority were male (88%) with a mean age of 62 years. Two-thirds of participants (67%) reported ever utilizing AUD treatment and 32% reported utilizing AUD treatment in the past 12 months. Compared with those who did not utilize AUD treatment, participants who utilized lifetime or past 12-month AUD treatment were younger, had lower LDQoL scores, and had higher scores on current symptoms of anxiety, depression, and problematic drinking. In multivariable analyses, the odds of ever utilizing pharmacological treatment alone or both behavioral and pharmacological treatment (vs. none) were lower with older age or higher LDQoL, and higher among those with a history of anxiety/depressive disorder. For past 12-month treatment utilization, odds were lower with older age, and higher among those with current clinically significant anxiety/depression or problematic drinking.

conclusionsPatients with alcohol-associated cirrhosis who were younger or had anxiety/depression and problematic drinking were more likely to utilize AUD treatment. To improve AUD treatment utilization, targeted outreach to patients less likely to receive care and the provision of integrated ALD and AUD treatment is warranted.

Indexed as

alcohol‐associated liver diseasehealth disparitiesmental healthquality of lifevulnerable populations

Identifiers

PMID39632077
PMCPMC11747812

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.